MSLN.CAR-IL-15 iNK mediated specific killing against MSLN-positive tumor cells and led to the selective expansion of MSLNlow tumor cells, highlighting that antigen loss is always a concern for CAR-directed cellular therapy (48). Here, IL15 is linked to neoplasm.